TY - JOUR
AU1 - Javid, Hossein
AU2 - Sharbaf Mashhad, Alireza
AU3 - Yazdani, Shaghayegh
AU4 - Akbari Oryani, Mahsa
AU5 - Akbari, Sanaz
AU6 - Rezagholinejad, Nastaran
AU7 - Tajaldini, Mahboubeh
AU8 - Karimi‐Shahri, Mehdi
AB - Despite great medical advances, oncological research is still looking for novel therapeutic approaches due to the limitation of conventional therapeutic agents. Virotherapy is one of these new emerging therapeutic approaches that attract attention with their widespread applications. Virotherapy use lives oncolytic viruses or genetically engineered viruses that selectively infect the tumor cells, replicate, and disrupt the cancerous cells that also induce their anticancer activity by stimulating the host antitumor immune response. Moreover, viruses are widely used as target delivery vectors for specifically delivering different genes, therapeutic agents, and immune‐stimulating agents. In addition to having antitumor activity by themselves in combination with conventional therapeutic agents like immune therapy and chemotherapy, Virotherapy agents also elicit promising outcomes. Therefore, in addition to their promising result in monotherapy use, virotherapy agents can also be used in combination with conventional cancer therapy, epigenetic modulators, and even microRNAs without any cross‐resistance, which allows the patient not to be deprived of her routine medicine. Still, this combination therapy reduces the adverse effect of the conventional therapies. All together suggest that virotherapy agents as novel potential agents in the field of cancer therapy.
TI - The role of viruses in cancer development versus cancer therapy: An oncological perspective
JF - Cancer Medicine
DO - 10.1002/cam4.5694
DA - 2023-05-01
UR - https://www.deepdyve.com/lp/wiley/the-role-of-viruses-in-cancer-development-versus-cancer-therapy-an-3U8LO20b7U
SP - 11127
EP - 11148
VL - 12
IS - 10
DP - DeepDyve
ER -